---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Complement c3 inhibitors"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Complement c3 inhibitors. Topics: Pegcetacoplan: mechanism and FDA approval; Pegcetacoplan: indication, dosage, and contraindications; Pegcetacoplan: retinal vasculitis and retinal vascular occlusion warning; Pegcetacoplan: neovascular AMD, intraocular inflammation, and ischemic optic neuropathy; 7 further topics. 11 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/complement-c3-inhibitors"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Complement c3 inhibitors

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Complement C3 Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

### Pegcetacoplan: mechanism and FDA approval

> “On February 17, 2023, pegcetacoplan 15 mg (Syfovre, Apellis Pharmaceuticals) was approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “Pegcetacoplan is a polyethylene-glycolylated (PEGylated) peptide that blocks complement factor C3, which has been implicated in the development of both the exudative and advanced atrophic forms of AMD.”

Source: [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)

<a id="topic-2.2.2.1.3-2"></a>

### Pegcetacoplan: indication, dosage, and contraindications

> “SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “SYFOVRE must be administered by a qualified physician.”
> “The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.”
> “SYFOVRE is contraindicated in patients with active intraocular inflammation.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-3"></a>

### Pegcetacoplan: retinal vasculitis and retinal vascular occlusion warning

> “Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE”
> “Cases may occur with the first dose of SYFOVRE and may result in severe vision loss.”
> “Discontinue treatment with SYFOVRE in patients who develop these events.”
> “Eye disorders: retinal vasculitis with or without retinal vascular occlusion.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### Pegcetacoplan: neovascular AMD, intraocular inflammation, and ischemic optic neuropathy

> “In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24.”
> “Patients receiving SYFOVRE should be monitored for signs of neovascular AMD.”
> “In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare.”
> “Optic ischemic neuropathy was reported in 1.7% of patients treated monthly, 0.2% of patients treated every other month and 0.0% of patients assigned to sham.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### OAKS and DERBY: design

> “The safety and efficacy of SYFOVRE were assessed in two multi-center, randomized, sham-controlled studies in patients with GA (atrophic nonexudative age-related macular degeneration), with or without subfoveal involvement, secondary to AMD in a total of 1258 randomized patients (SYFOVRE 839 patients, sham 419 patients).”
> “There was a reduction in the mean rate of GA lesion growth observed in both studies.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

### OAKS and DERBY: GA lesion growth from baseline to month 24

| Study and group | Rate of GA lesion area growth (mm2), slope (SE) | Difference (95% CI) in slope from sham pooled | Percent difference from sham pooled |
| --- | --- | --- | --- |
| OAKS, pegcetacoplan monthly | “3.11 (0.148)” | “−0.87” “(−1.27 to −0.47)” | “−21.9%” |
| OAKS, pegcetacoplan every other month | “3.26 (0.134)” | “−0.72” “(−1.10 to −0.33)” | “−18.1%” |
| OAKS, sham pooled | “3.98 (0.143)” | “NA” | “NA” |
| DERBY, pegcetacoplan monthly | “3.28 (0.125)” | “−0.73” “(−1.14 to −0.31)” | “−18.1%” |
| DERBY, pegcetacoplan every other month | “3.31 (0.129)” | “−0.70” “(−1.11 to −0.28)” | “−17.4%” |
| DERBY, sham pooled | “4.00 (0.169)” | “NA” | “NA” |

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

### OAKS and DERBY: primary endpoint at month 12 and visual function endpoints

> “The primary endpoint was the change from baseline to month 12 in the total area of geographic atrophy lesions in the study eye based on fundus autofluorescence imaging”
> “In DERBY, pegcetacoplan monthly and pegcetacoplan every other month slowed geographic atrophy lesion growth, although it did not reach significance, by 12%”
> “There were no differences in key secondary visual function endpoints at 24 months.”

Source: [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/)

<a id="topic-2.2.2.1.3-8"></a>

### OAKS and DERBY: guideline summary of lesion growth reductions

> “In OAKS, the primary endpoint at 12 months was met with monthly pegcetacoplan reducing GA growth by 21% compared with sham and EOM pegcetacoplan reducing GA growth by 16%.”
> “At 24 months, monthly pegcetacoplan and EOM pegcetacoplan reduced the GA growth rate by 22% and 18% compared with sham, respectively.”
> “Subgroup analysis of the eyes with non-foveal-involving GA showed reduced growth rates by 26% in the monthly arm and 23% in the EOM arm compared with sham.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.3-9"></a>

### GALE open-label extension: up to 36 months of pegcetacoplan

> “Through the first 12 months of GALE, 92.0% (727/790) patient retention was observed.”
> “Across all eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of change in GA area up to 32% versus projected sham.”
> “Adverse events included 33 (4.5%) eyes with exudative AMD, 15 (1.9%) intraocular inflammation (classified as mild or moderate in severity), 1 (0.1%) ischemic optic neuropathy, and 1 (0.1%) infectious endophthalmitis.”
> “No events of vasculitis were reported.”

Source: [Wykoff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40280279/)

<a id="topic-2.2.2.1.3-10"></a>

### GALE open-label extension: up to 48 months, early versus delayed treatment

> “The delayed treatment group included sham-observed eyes from OAKS and DERBY which crossed over at 24 months to receive pegcetacoplan treatment for 24 months in the GALE OLE.”
> “In the overall population, 48 continuous months of pegcetacoplan treatment reduced GA area growth rate by up to 24% compared with projected sham, translating to 1.88 mm2 of retinal tissue.”
> “GALE safety data were consistent with the findings of the OAKS and DERBY studies.”

Source: [Dhoot et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665201/)

<a id="topic-2.2.2.1.3-11"></a>

### Pegcetacoplan: postmarketing retinal vasculitis case series

> “Fourteen eyes of 13 patients were confirmed to have retinal vasculitis by review of imaging studies.”
> “All cases occurred after the first pegcetacoplan injection.”
> “Occlusive retinal vasculopathy was confirmed in 11 eyes (79%).”
> “Eight eyes (57%) had more than a 3-line decrease in VA, and 6 eyes (43%) had more than a 6-line decrease in VA from baseline to the final follow-up, including 2 eyes that were enucleated.”

Source: [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
